Disease · MONDO_0004849
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Zemaira® vs Placebo: serious adverse events | 28 of 93 | 28 of 87 | 180 | NCT00261833 | Trial comparisons |
| Tetomilast 25 mg vs Placebo: serious adverse events | 13 of 51 | 12 of 33 | 84 | NCT00874497 | Trial comparisons |
| Prolastin (60 mg/kg Body Weight) vs Placebo: serious adverse events | 9 of 38 | 15 of 39 | 77 | NCT00263887 | Trial comparisons |
| MMF - Cystic Fibrosis vs MMF - COPD, Emphysema, IPF, or A1AD: serious adverse events | 13 of 33 | 14 of 35 | 68 | NCT01014442 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: Numbers and % of Subjects Who Experience at Least 1 Treatment-emergent Adverse Event | 25 of 32 | 23 of 31 | 63 | NCT03679598 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: deaths from any cause | 0 of 32 | 0 of 31 | 63 | NCT03679598 | Trial comparisons |
| Alvelestat (MPH966) vs Placebo: serious adverse events | 0 of 32 | 0 of 31 | 63 | NCT03679598 | Trial comparisons |
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Potentially Related to Presence of Particle Load in the GLASSIA Solution | 0 of 18 | 0 of 16 | 34 | NCT02525861 | Trial comparisons |
| Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 13 of 18 | 9 of 16 | 34 | NCT02525861 | Trial comparisons |
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 24 Hours Following the End of IP Infusion | 7 of 18 | 3 of 16 | 34 | NCT02525861 | Trial comparisons |
| GLASSIA (High-end) vs GLASSIA (Low-end): deaths from any cause | 0 of 18 | 0 of 16 | 34 | NCT02525861 | Trial comparisons |
Cohort I: GLASSIA (High-end) vs Cohort II: GLASSIA (Low-end): Number of Participants With Treatment-Emergent Adverse Reactions (ARs) Plus Suspected Adverse Reactions (ARs) Within 72 Hours Following the End of IP Infusion | 10 of 18 | 7 of 16 | 34 | NCT02525861 | Trial comparisons |
| GLASSIA (High-end) vs GLASSIA (Low-end): serious adverse events | 1 of 18 | 1 of 16 | 34 | NCT02525861 | Trial comparisons |
| Aspirin vs Placebo: deaths from any cause | 0 of 14 | 0 of 15 | 29 | NCT03008915 | Trial comparisons |
| Aspirin vs Placebo: serious adverse events | 0 of 14 | 0 of 15 | 29 | NCT03008915 | Trial comparisons |
| Doxycycline vs Placebo (Sugar Pill): Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. | 3 of 16 | 1 of 8 | 24 | NCT01744093 | Trial comparisons |
| Doxycycline vs Placebo (Sugar Pill): Tolerability of Doxycycline, as Measured by the Number of Subjects With a Dose-limiting Toxicity | 1 of 16 | 1 of 8 | 24 | NCT01744093 | Trial comparisons |
| Doxycycline vs Placebo (Sugar Pill): deaths from any cause | 0 of 16 | 0 of 8 | 24 | NCT01744093 | Trial comparisons |
| Doxycycline vs Placebo (Sugar Pill): serious adverse events | 0 of 16 | 0 of 8 | 24 | NCT01744093 | Trial comparisons |
| Belimumab vs Placebo: deaths from any cause | 0 of 10 | 0 of 6 | 16 | NCT03244059 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0004849/comparisons